IVDR vs IVDD Classification: Key Regulatory Changes Every IVD Manufacturer Should Understand



IVDR vs IVDD Classification: Understanding the Major Regulatory Changes for IVD Manufacturers


The European regulatory framework for in vitro diagnostic medical devices underwent a significant transformation when Regulation (EU) 2017/746 replaced the previous In Vitro Diagnostic Medical Devices Directive 98/79/EC. This change affected how diagnostic products are classified, assessed, documented, and approved for the European market.


Under the previous IVDD system, products were grouped into specific categories, including Annex II List A, Annex II List B, self-testing devices, and other devices. The IVDR introduced a broader risk-based classification framework consisting of four classes: A, B, C, and D. This change brought many more IVD products within the scope of notified body assessment.


For manufacturers already selling diagnostic products in Europe, understanding the differences between IVDD and IVDR classification is essential. I3CGlobal provides regulatory information and consulting services related to IVDR classification, technical documentation, and CE marking to help manufacturers understand the new requirements.



Understanding the Previous IVDD Classification Framework


The former In Vitro Diagnostic Medical Devices Directive, Directive 98/79/EC, used a classification structure based on specific product lists and intended applications.


Under this framework, Annex II contained List A and List B devices. Certain self-testing devices were also subject to notified body involvement. Many other IVD products could be self-declared by manufacturers without the same level of external conformity assessment.



Annex II List A Devices


List A included certain higher-risk diagnostic devices, including products associated with blood grouping and screening for specified infectious agents. These products were subject to notified body involvement and additional regulatory requirements.



Annex II List B Devices


List B included other diagnostic products identified by the directive as requiring additional conformity assessment. The category covered specified blood grouping and infectious disease testing applications, among other products listed in the relevant annex.



Other IVD Products


Many products outside the specified lists and self-testing categories could follow a manufacturer self-declaration route. This meant that a significant proportion of IVD products did not require notified body involvement under the previous framework.



Why the IVDR Introduced a Different Classification Approach


The IVDR moved away from the limited list-based system and adopted a risk-based classification approach aligned with principles developed by the Global Harmonization Task Force and subsequently reflected in IMDRF work.


The objective was to create a classification framework that better considered the potential consequences of incorrect diagnostic results for individual patients and public health.


Under the new approach, manufacturers must assess their devices against the seven rules in Annex VIII. The applicable rule depends on the intended purpose, diagnostic application, target condition, and associated risks.



The Four IVDR Classes Compared With the Previous System


The IVDR establishes four risk classes, each with different conformity assessment requirements.



Class A: Low Risk


Class A includes specified general laboratory products, buffers, washing solutions, culture media, histological stains, instruments intended for IVD procedures, and specimen receptacles. Most Class A devices can be self-declared by manufacturers, although sterile Class A products require notified body involvement for the applicable sterility-related manufacturing aspects.



Class B: Moderate Individual Risk


Class B includes devices not captured by the higher-risk rules, along with certain specified self-tests and controls without assigned values. Manufacturers must involve a notified body in the applicable conformity assessment process.



Class C: High Individual Risk


Class C covers several important diagnostic applications, including cancer testing, genetic testing, companion diagnostics, prenatal screening, and many infectious disease tests. Most self-testing devices also fall into this category, subject to the specified exceptions.



Class D: High Individual and Public Health Risk


Class D covers specified high-risk infectious disease screening and critical blood grouping applications. These devices are subject to extensive assessment requirements, including applicable EU reference laboratory activities and batch verification.



Which Devices Experienced the Biggest Classification Changes?


The introduction of the IVDR affected products that previously fell outside the limited IVDD lists. Some diagnostic tests that could previously follow self-declaration may now be classified as Class B or Class C and require notified body assessment.


Infectious disease assays, genetic tests, oncology markers, and other diagnostic products are examples of areas where the new classification framework can result in additional regulatory obligations.



Infectious Disease Diagnostics


Infectious disease tests must be evaluated according to the specific organism, disease severity, propagation risk, intended application, and potential consequences of an incorrect result. Some applications fall under Class C, while others may meet the criteria for Class D.


Manufacturers should avoid assuming that all infectious disease assays receive the same classification. The applicable provisions of Annex VIII must be examined individually.



Genetic and Oncology Testing


Genetic tests and products intended for cancer screening, diagnosis, or staging are important examples of applications covered by Rule 3. Their classification can influence the level of technical documentation assessment and performance evidence required.



How Notified Body Involvement Changed Under IVDR


One of the most important practical changes is the increased involvement of notified bodies. Under the IVDD, many products could be self-declared. Under the IVDR, Class B, C, and D devices generally require notified body assessment.


For Class B devices, the conformity assessment may involve a quality management system audit and assessment of representative technical documentation. Certain self-testing and near-patient testing devices require additional device-specific assessment.


Class C devices generally require more extensive technical documentation assessment. Companion diagnostics have additional consultation requirements, while Class D devices face the most extensive assessment provisions, including applicable EU reference laboratory activities.



What IVDD Manufacturers Must Do When Moving to IVDR


Manufacturers transitioning from the previous directive should not simply transfer their old classification into the new regulatory documentation. Every device must be evaluated under the current Annex VIII rules.


The transition exercise should include a review of intended purpose, labelling, instructions for use, technical documentation, performance evidence, quality management processes, and conformity assessment requirements.



Review Every Product in the Portfolio


Manufacturers with several diagnostic products should prepare a product-by-product classification assessment. Different assays within the same portfolio may have different intended purposes and risk categories.


A portfolio-level review can help identify which products require notified body assessment and which may follow the Class A self-declaration route.



Update Technical Documentation


Technical documentation must be aligned with the IVDR requirements. This includes applicable information relating to device description, intended purpose, design and manufacturing information, risk management, performance evaluation, labelling, and post-market activities.


The documentation should also contain a clear classification rationale explaining the selected Annex VIII rule and final class.



Planning Notified Body Capacity and Transition Activities


Increased notified body involvement can create planning challenges for manufacturers. Companies should identify their conformity assessment route early and consider notified body availability, technical documentation preparation, quality management readiness, and applicable transition provisions.


Transition arrangements under the IVDR have been amended over time. Eligibility depends on the relevant device category and compliance with the applicable legal conditions. Manufacturers should consult the current consolidated regulation and official European Commission guidance rather than relying on outdated transition dates.



The Importance of Professional IVDR Classification Support


Classification decisions can become complex when a product has several diagnostic applications, software components, or different intended users. A regulatory review can help manufacturers understand which rules apply and what supporting documentation is required.


I3CGlobal provides information and consulting services covering IVDR classification, IVDR CE marking, technical files, and related regulatory activities. Its IVDR classification guide explains the risk classes and the changes introduced by the new regulation.



Conclusion


The transition from IVDD to IVDR introduced a more comprehensive risk-based classification system for in vitro diagnostic devices. The four classes and seven Annex VIII rules replaced the previous list-based structure and brought many additional products within the scope of notified body assessment.

Manufacturers should review IVDR Classification their entire IVD portfolio, reassess intended purposes, update classification rationales, and prepare the required technical documentation. Understanding these changes is essential for planning IVDR Classification a suitable IVDR conformity assessment pathway and maintaining regulatory readiness in the European market.

Leave a Reply

Your email address will not be published. Required fields are marked *